2-(MORFOLIN-4-IL)-1,7-NAFTIRIDINAS

Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son independientemente hidrogeno o metilo, adicionalmente se refiere a una compuesto Ib, donde: R1 es 1H-pirazol-3-il, R2 es hidrogeno, halogeno,...

Full description

Saved in:
Bibliographic Details
Main Authors KOPPITZ, Marcus, EBERSPACHER, Uwe, WORTMANN, Lars, SIEMEISTER, Gerhard, WEDLER, Christine, BADER, Benjamin, MOOSMAYER, Dieter, VON NUSSBAUM, Franz, LUCKING, Ulrich, WENGNER, Antje Margret, BONE, Wilhelm, LIENAU, Philip, SCHICK, Hans, LEFRANC, Julien, BRIEM, Hans, EIS, Knut, GRUDZINSKA-GOEBEL, Joanna
Format Patent
LanguageSpanish
Published 15.06.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son independientemente hidrogeno o metilo, adicionalmente se refiere a una compuesto Ib, donde: R1 es 1H-pirazol-3-il, R2 es hidrogeno, halogeno, entre otros; R4 es hidrogeno o metilo. Son compuestos preferidos: 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-N-etoxicarbonil-S-metilsulfoximida; 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-S-metilsulfoximida; entre otros. Tambien se refiere a una composicion y a una combinacion farmaceutica. Dichos compuestos derivados de 2-(morfolin-4-il)-1,7-naftiridina son utiles en el tratamiento de enfermedades hiperproliferativas The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
AbstractList Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son independientemente hidrogeno o metilo, adicionalmente se refiere a una compuesto Ib, donde: R1 es 1H-pirazol-3-il, R2 es hidrogeno, halogeno, entre otros; R4 es hidrogeno o metilo. Son compuestos preferidos: 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-N-etoxicarbonil-S-metilsulfoximida; 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-S-metilsulfoximida; entre otros. Tambien se refiere a una composicion y a una combinacion farmaceutica. Dichos compuestos derivados de 2-(morfolin-4-il)-1,7-naftiridina son utiles en el tratamiento de enfermedades hiperproliferativas The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.
Author LUCKING, Ulrich
BONE, Wilhelm
BADER, Benjamin
WORTMANN, Lars
EIS, Knut
WEDLER, Christine
EBERSPACHER, Uwe
SCHICK, Hans
LEFRANC, Julien
MOOSMAYER, Dieter
WENGNER, Antje Margret
BRIEM, Hans
KOPPITZ, Marcus
VON NUSSBAUM, Franz
GRUDZINSKA-GOEBEL, Joanna
LIENAU, Philip
SIEMEISTER, Gerhard
Author_xml – fullname: KOPPITZ, Marcus
– fullname: EBERSPACHER, Uwe
– fullname: WORTMANN, Lars
– fullname: SIEMEISTER, Gerhard
– fullname: WEDLER, Christine
– fullname: BADER, Benjamin
– fullname: MOOSMAYER, Dieter
– fullname: VON NUSSBAUM, Franz
– fullname: LUCKING, Ulrich
– fullname: WENGNER, Antje Margret
– fullname: BONE, Wilhelm
– fullname: LIENAU, Philip
– fullname: SCHICK, Hans
– fullname: LEFRANC, Julien
– fullname: BRIEM, Hans
– fullname: EIS, Knut
– fullname: GRUDZINSKA-GOEBEL, Joanna
BookMark eNrjYmDJy89L5WRQMtLV8PUPcvP38fTTNdH19NHUNdQx1_VzdAvxDPJ08fRzDOZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfEBrkYGhuYGZmZmjobGxKgBAMHnI2w
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID PE20170666A1
GroupedDBID EVB
ID FETCH-epo_espacenet_PE20170666A13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:58:10 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Spanish
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_PE20170666A13
Notes Application Number: PE2017000168
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170615&DB=EPODOC&CC=PE&NR=20170666A1
ParticipantIDs epo_espacenet_PE20170666A1
PublicationCentury 2000
PublicationDate 20170615
PublicationDateYYYYMMDD 2017-06-15
PublicationDate_xml – month: 06
  year: 2017
  text: 20170615
  day: 15
PublicationDecade 2010
PublicationYear 2017
RelatedCompanies BAYER PHARMA AKTIENGESELLSCHAFT
RelatedCompanies_xml – name: BAYER PHARMA AKTIENGESELLSCHAFT
Score 2.9540942
Snippet Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title 2-(MORFOLIN-4-IL)-1,7-NAFTIRIDINAS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170615&DB=EPODOC&locale=&CC=PE&NR=20170666A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZS8QwEB6WVdQ3XRVdD1SkKBjskV4PRbo92Mr2oFbZt2UTW9AHXWzFv--kdF1f9C3JwOSAL18mmZkAXM4ZU22Ta4RrVCVUfzaJLasVQXKtKNKFwWURnBwnxviR3k_1aQ9el7EwbZ7QrzY5IiKKI96bdr9erC6x_Na3sr5lL9j0fhcWji911rHIBaPokj9ygiz1U0_yPCcLpCTvZIbhoqW0hsdoU6AheBqJqJTFb0oJt2E9Q21vzQ70ynoAm97y57UBbMTdgzcWO-zVu3Chkqs4zcN0EiWEkmhyTZQbkyRuWER55EeJ-7AH52FQeGOCnc1-ZjbLgtW4tH3oo8VfHsCZUso2t5kscrFRbltMq6y5pfOyqhCQJTuE4d96hv8Jj2BLVISvk6IfQ7_5-CxPkFUbdtouxzfU23ZK
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTkXnt0hRMNiPtF0fhmz9YNV-UevYW1liC_qgw1X8972UzvmibyEHl0vgl18uubsAXM4YUy2Ta4RrVCVUfzaJJaslQXItKdKFwWWRnBxGxviJ3k_1aQtel7kwdZ3Qr7o4IiKKI96rer-ery6xnDq2cnHLXrDr_c7LBo7UeMeiFoyiS85o4CaxE9uSbQ8SV4rSRmYYQ_SU1vCIbQo0uJORyEqZ_6YUbwvWE9T2Vm1Dq1h0oWMvf17rwkbYPHhjs8HeYgcuVHIVxqkXB35EKPGDa6LcmCQaepmf-o4fDR934dxzM3tMcLD8Z2Z54q7s0vagjR5_sQ9nSiFb3GKyqMVGudVnWtmf9XVelCUCsmAH0PtbT-8_4Sl0xlkY5GjpwyFsCoGIe1L0I2hXH5_FMTJsxU7qpfkGi3p5PQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=2-%28MORFOLIN-4-IL%29-1%2C7-NAFTIRIDINAS&rft.inventor=KOPPITZ%2C+Marcus&rft.inventor=EBERSPACHER%2C+Uwe&rft.inventor=WORTMANN%2C+Lars&rft.inventor=SIEMEISTER%2C+Gerhard&rft.inventor=WEDLER%2C+Christine&rft.inventor=BADER%2C+Benjamin&rft.inventor=MOOSMAYER%2C+Dieter&rft.inventor=VON+NUSSBAUM%2C+Franz&rft.inventor=LUCKING%2C+Ulrich&rft.inventor=WENGNER%2C+Antje+Margret&rft.inventor=BONE%2C+Wilhelm&rft.inventor=LIENAU%2C+Philip&rft.inventor=SCHICK%2C+Hans&rft.inventor=LEFRANC%2C+Julien&rft.inventor=BRIEM%2C+Hans&rft.inventor=EIS%2C+Knut&rft.inventor=GRUDZINSKA-GOEBEL%2C+Joanna&rft.date=2017-06-15&rft.externalDBID=A1&rft.externalDocID=PE20170666A1